Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Cellda Prostate for cancer diagnosis - regulatory and market evaluation

Reference number
Coordinator Cellda AB
Funding from Vinnova SEK 135 000
Project duration September 2024 - July 2025
Status Ongoing
Venture Medtech4Health: Competence Enhancement in SME
Call Medtech4Health: Competence Enhancement in Small Businesses 2024

Purpose and goal

The project consists of two parts. For the specified markets, the potential for the product Cellda® Prostate is evaluated, and potential partners for collaborations are identified. The goal is to further develop the company´s market strategy. The regulatory documentation for Cellda® Prostate is reviewed and supplemented. The aim is for it to be finalized in preparation for an upcoming clinical performance study and before submitting a certification application.

Expected effects and result

After the project, markets with the greatest potential for Cellda® Prostate have been prioritized and basis for starting collaborations with other actors as well as for funding of the company has been created . The regulatory documentation has been reviewed, areas for development and improvement have been identified and addressed. The overall expected results are that the project has contributed to Cellda® Prostate being ready for CE-proposal and has expanded knowledge of priority markets.

Planned approach and implementation

Hired consultants and experts will work with the company´s operational team to implement the project. The project manager calls joint project meetings to plan and follow up activities, identify tasks and reporting. The project manager ensures that the project´s implementation, results and conclusions are documented and implemented as well as that competence transfer is ensured.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 21 May 2025

Reference number 2024-02092